Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration (FDA) has today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
Eli Lilly has acquired worldwide rights to Locemia’s intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin.
Johnson & Johnson has started a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies.
Novartis has announced new late-breaking data demonstrating that Cosentyx (secukinumab) provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable safety profile across three years.
Allergan’s researchers have presented data at IDWeek from the International Network for Optimal Resistance Monitoring (INFORM) program that monitors the prevalence of resistant bacteria and changing trends of resistance, as well as the in vitro activity of antibiotics against these pathogens.
Eli Lilly and Company and Innovent Biologics, Inc. has announced an expansion of their drug development collaboration, already one of the largest in China between a multi-national and domestic biopharmaceutical company.
Premaitha Health plc, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT), has announced the results of a study on the first-trimester detection of trisomy 21, 18 and 13 using the IONA test.
A research-based healthcare company, Roche, has bought Adheron Therapeutics
Allergan plc has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Allergan’s supplemental New Drug Application (sNDA), for MRSA.